A GLP-1 receptor agonist and the most clinically validated weight loss injectable available — FDA-approved as Ozempic and Wegovy, now widely accessible through compounding telehealth.
| Provider | Type | Price | Review | Link |
|---|---|---|---|---|
| Maximus | Telehealth | $199/mo | Read review | Get Started → |
| MYRNK | Telehealth | $129+/mo | Read review | Get Started → |
| PeterMD | Telehealth | $150/mo | Read review | Get Started → |
| MadeMed | Telehealth | $199/mo | Read review | Get Started → |
| Marek Health | Telehealth | $166/mo | Read review | Get Started → |
| Limitless Alt Med | Telehealth | $115–$275/mo | Read review | Get Started → |
| NextGenPeps | Research | Unavailable | — | Visit Site → |
Telehealth = physician-prescribed. Research = for research use only, no prescription required. Learn the difference →
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It mimics the naturally occurring GLP-1 hormone released after meals, binding to receptors in the pancreas, gut, and brain to reduce appetite, slow gastric emptying, and improve insulin sensitivity.
In the landmark STEP trials, semaglutide at 2.4mg/week produced an average 15–17% reduction in body weight over 68 weeks — far outperforming prior weight loss medications. The STEP 1 trial (n=1,961) showed ~15% mean weight loss vs ~2.4% for placebo. Cardiovascular benefit data (SELECT trial) further cemented its standing as the most evidence-backed weight loss drug available.
Most users notice reduced appetite and early satiety within the first 1–2 weeks. Meaningful weight loss typically becomes visible by weeks 4–8. The dose titration schedule — starting low and increasing over months — minimizes GI side effects like nausea and helps the body adapt. Compounded semaglutide from telehealth clinics delivers the same active molecule at a fraction of brand-name cost.
Because semaglutide is FDA-approved and requires a prescription, telehealth is the primary access route for compounded versions. Research-grade semaglutide is currently unavailable through NextGenPeps due to regulatory constraints.